← Leaderboards
Gary D Slade
University Of North Carolina Chapel Hill
$13,339,302
Attributed
$33,996,534
Total exposure
16
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.2M · FY2008–25$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$33,996,534 · 16
By mechanism
U01$22,122,354 · 2
UH3$5,443,761 · 1
UH2$1,472,781 · 1
P01$1,188,315 · 1
UG3$651,121 · 1
R03$589,915 · 2
Top collaborators
- Roger B Fillingim13 shared
- William Maixner9 shared
- Samuel Arbes8 shared
- Inna Evgenievna Tchivileva8 shared
- Richard Ohrbach7 shared
- Luda Diatchenko6 shared
- Joel D. Greenspan6 shared
- Shamil Sunyaev6 shared
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- John Douglas Mann$8,814,214
- Ray C Williams$233,569
Others in their field
Top investigators on “Affect”
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$287,585,588
- Chanza Baytop · Westat, Inc.$271,217,917
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$209,385,844
- David Heimbrook · Leidos Biomedical Research, Inc.$168,138,264
- Daniel R Kuritzkes · Brigham And Women'S Hospital$151,687,019
Research focus
AffectFollow-UpPainVariantEnrollmentSamplingRisk FactorsGeneticSymptomsResearch PersonnelChronicPersistent PainResponseTemporomandibular Joint DisordersProtocols DocumentationGenesCohortOral HealthGenotypeNational Institute Of Dental And Craniofacial ResearchEtiologyCharacteristicsEvaluationReporting
Grant awards (51)
Phase II, proof-of-concept randomized controlled trial to evaluate dental caries preventive effects of fluoridated bottle water$1,182,461
UH3 · FY2025 · DE · contact PI
Phase II, proof-of-concept randomized controlled trial to evaluate dental caries preventive effects of fluoridated bottle water$1,148,810
UH3 · FY2024 · DE · contact PI
Phase II, proof-of-concept randomized controlled trial to evaluate dental caries preventive effects of fluoridated bottle water$998,561
UH3 · FY2023 · DE · contact PI
PUFA metabolism for prevention and treatment of TMD pain: an interdisciplinary, translational approach.$314,704
R34 · FY2023 · DE · contact PI
Phase II, proof-of-concept randomized controlled trial to evaluate dental caries preventive effects of fluoridated bottle water$1,064,773
UH3 · FY2022 · DE · contact PI
Phase II, proof-of-concept randomized controlled trial to evaluate dental caries preventive effects of fluoridated bottle water$1,049,156
UH3 · FY2021 · DE · contact PI
Phase II, proof-of-concept randomized controlled trial to evaluate dental caries preventive effects of fluoridated bottle water$651,121
UG3 · FY2020 · DE · contact PI
Effect of COMT genetic polymorphisms on response to propranolol therapy in Temporomandibular Disorder$558,218
U01 · FY2018 · DE
Effect of COMT genetic polymorphisms on response to propranolol therapy in TMD$465,721
U01 · FY2017 · DE
Is Periodontal Disease Involved in the Etiology of Non-Alcoholic Fatty Liver Disease$152,000
R03 · FY2017 · DE · contact PI
Genetic and Psychosocial Influences on Transition to Chronic TMD and Related Pain$2,796,628
U01 · FY2016 · DE · contact PI
Effect of COMT genetic polymorphisms on response to propranolol therapy in TMD$1,057,143
U01 · FY2016 · DE
Sociopolitical Policies That Reduce Disparities in Children's Oral Health$882,364
UH2 · FY2016 · DE
Proteins, MicroRNAs and Genes Associated with TMD and Overlapping Pain Conditions$586,001
R56 · FY2016 · DE
Effect of COMT genetic polymorphisms on response to propranolol therapy in TMD$272,798
U01 · FY2016 · DE
Biomedical Researcher Development Program in TMJD and Orofacial Pain$245,051
K12 · FY2016 · DE
Genetic and Psychosocial Influences on Transition to Chronic TMD and Related Pain$171,998
U01 · FY2016 · DE · contact PI
Is Periodontal Disease Involved in the Etiology of Non-Alcoholic Fatty Liver Disease$152,000
R03 · FY2016 · DE · contact PI
Genetic and Psychosocial Influences on Transition to Chronic TMD and Related Pain$3,399,224
U01 · FY2015 · DE · contact PI
Effect of COMT genetic polymorphisms on response to propranolol therapy in TMD$1,140,009
U01 · FY2015 · DE
Sociopolitical Policies That Reduce Disparities in Children's Oral Health$590,417
UH2 · FY2015 · DE
Biomedical Researcher Development Program in TMJD and Orofacial Pain$212,111
K12 · FY2015 · DE
Genetic and Psychosocial Influences on Transition to Chronic TMD and Related Pain$71,782
U01 · FY2015 · DE
Effect of COMT genetic polymorphisms on response to propranolol therapy in TMD$66,223
U01 · FY2015 · DE
Genetic and Psychosocial Influences on Transition to Chronic TMD and Related Pain$2,890,056
U01 · FY2014 · DE
Effect of COMT genetic polymorphisms on response to propranolol therapy in TMD$1,175,748
U01 · FY2014 · DE
Etiology and Modeling Core$215,720
P01 · FY2014 · NS · contact PI
Genetic and Psychosocial Influences on Transition to Chronic TMD and Related Pain$4,146,067
U01 · FY2013 · DE
Etiology and Modeling Core$335,658
P01 · FY2013 · NS · contact PI
Effects of cumulative stress and change in pain regulation on risk of chronic TMD$139,989
R03 · FY2013 · DE · contact PI
Genetic and Psychosocial Influences on Transition to Chronic TMD and Related Pain$3,910,739
U01 · FY2012 · DE
Effect of COMT genetic polymorphism on response to propranolol therapy in TMD$238,744
R34 · FY2012 · DE
Etiology and Modeling Core$201,649
P01 · FY2012 · NS · contact PI
Effects of cumulative stress and change in pain regulation on risk of chronic TMD$145,926
R03 · FY2012 · DE · contact PI
Etiology and Modeling Core$35,016
P01 · FY2012 · NS · contact PI
Etiology and Modeling Core$199,963
P01 · FY2011 · NS · contact PI
Etiology and Modeling Core$200,309
P01 · FY2010 · NS · contact PI
Planning for International Studies of Population Oral Health Determinants$131,324
R21 · FY2009 · DE · contact PI
Planning for International Studies of Population Oral Health Determinants$106,337
R21 · FY2008 · DE · contact PI
ACUTE PHASE REACTANTS IN PERIODONTITIS AND CARDIOVASCULAR DISEASE$12,506
P60 · FY2002 · DE
ACUTE PHASE REACTANTS IN PERIODONTITIS AND CARDIOVASCULAR DISEASE$12,506
P60 · FY2002 · DE
EFFECTS OF ORAL AND SYSTEMIC DISEASE ON QUALITY OF LIFE$1
P60 · FY2002 · DE
EFFECTS OF ORAL AND SYSTEMIC DISEASE ON QUALITY OF LIFE$1
P60 · FY2002 · DE
QUALITY OF LIFE OUTCOMES FOR ORAL HEALTH CARE$75,624
R29 · FY2001 · DE
ACUTE PHASE REACTANTS IN PERIODONTITIS AND CARDIOVASCULAR DISEASE$12,506
P60 · FY2001 · DE
EFFECTS OF ORAL AND SYSTEMIC DISEASE ON QUALITY OF LIFE$1
P60 · FY2001 · DE
ACUTE PHASE REACTANTS IN PERIODONTITIS AND CARDIOVASCULAR DISEASE$116,783
P60 · FY2000 · DE
ACUTE PHASE REACTANTS IN PERIODONTITIS AND CARDIOVASCULAR DISEASE$116,783
P60 · FY2000 · DE
EFFECTS OF ORAL AND SYSTEMIC DISEASE ON QUALITY OF LIFE$116,779
P60 · FY2000 · DE
EFFECTS OF ORAL AND SYSTEMIC DISEASE ON QUALITY OF LIFE$116,779
P60 · FY2000 · DE
QUALITY OF LIFE OUTCOMES FOR ORAL HEALTH CARE$113,746
R29 · FY2000 · DE